RNL Bio aims to conduct Phase IIb trials for RNL-JointStem for osteoarthritis in US

Published: 2013-05-06 06:56:00

Updated: 2013-05-06 06:56:00

RNL Bio, a stem cell biotechnology company, said Thursday that it has filed an Investigational New Drug application (IND) with the US Food and Drug Administration to start phase IIb clinical trials with its adipose-derived stem cell product, termed RNL-JointStem, for the treatment of osteoarthrit...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK